Skip to main content
LMED
OTC Technology

LataMed Q3 10-Q: Zero Cash, $198,329 Nine-Month Loss, Going Concern Stands

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Technology
Sentiment info
Negative
Importance info
8
Price
$0.037
Mkt Cap
$6.595M
52W Low
$0.026
52W High
$135.002
52W Position info
40% above low
Off High info
100% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

LMED sits 40% above its 52-week low of $0.026 on light trading volume (0.1× avg).

Summary

LataMed's Q3 10-Q shows zero cash, a nine-month net loss of $198,329 and a $29.8M accumulated deficit, with management repeating its going concern warning and no committed financing in place.


Key Events · Earnings and Guidance · LMED

  • Zero Cash, Going Concern Reiterated

    Cash was $0 at September 30, 2026, and management states the $198,329 nine-month net loss and $29,799,115 accumulated deficit raise substantial doubt about the ability to continue as a going concern.

  • Loss Widens Year Over Year

    Q3 net loss was $58,108 versus $36,302 in Q3 2025; the nine-month loss was $198,329 versus $89,939, driven by higher professional fees and interest expense.

  • Debt-Funded Operations

    The company issued $117,084 of 10% promissory notes due on demand in the nine months, lifting notes payable to $389,388 from $272,304; the working capital deficit widened to $829,189 from $630,860.

  • No Committed Financing

    Management says it has no firm agreements for financing and intends to pursue a private equity offering, warning that any equity raise may involve substantial dilution.


Analysis · LMED · Technology

With no revenue and no cash on the balance sheet at September 30, 2026, LataMed's nine-month net loss widened to $198,329 from $89,939 a year earlier. The accumulated deficit now stands at $29,799,115, and management repeats that these conditions raise substantial doubt about the company's ability to continue as a going concern. The only funding in the period was $117,084 of new 10% promissory notes, which pushed total notes payable to $389,388 against a working capital deficit of $829,189. No firm financing agreements are in place; the company plans to seek a private equity offering, which would mean further dilution for existing holders. Disclosure controls were again deemed not effective.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LMED was trading at $0.04 on OTC in the Technology sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $0.03 to $135.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LMED - Latest Insights

LMED
Aug 11, 2026, 3:01 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.660
Real-time Price: $0.0365 info
Change: -$0.6235 (-94%) info
Market Cap: $6.595M info
LMED
Jul 08, 2026, 7:05 AM EDT
Source: EQS
Importance Score:
7
Price at Filing: $3.85
Real-time Price: $0.0365 info
Change: Stock Split info
Market Cap: $6.595M info
LMED
Jun 30, 2026, 8:53 AM EDT
Source: EQS
Importance Score:
7
Price at Filing: $3.55
Real-time Price: $0.0365 info
Change: Stock Split info
Market Cap: $6.595M info
LMED
Jun 15, 2026, 9:05 AM EDT
Source: EQS
Importance Score:
7
Price at Filing: $2.44
Real-time Price: $0.0365 info
Change: Stock Split info
Market Cap: $6.595M info
LMED
May 20, 2026, 2:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.73
Real-time Price: $0.0365 info
Change: Stock Split info
Market Cap: $6.595M info